Be empowered with MS views and news. CLICK HERE - - to SUBSCRIBE for The MS BEACON e-Newsletter
Saturday, January 17, 2015
Aubagio is used to prolong abilities of people with relapsing remitting MS
Aubagio, a drug used to prolong abilities of people with relapsing remitting MS, is now covered under the Yukon Government's drug plan. (Mark Blinch/ Reuters)
Linda Friesen says she left her wheelchair behind in India after undergoing experimental therapy
Please know that this is NOT an official survey. We are doing this for a person who has a question.
We hope to receive sincere responses that can be read by the person who asked us to learn the answers to the questions showing below.
PLEASE do not respond or comment on Facebook or Twitter as the answers must be posted to this blog if any we are to receive any answers and then this will be available from just this one focal point.
If reading this from social media, please click this link, to access the original source of this blog posting so you can leave your comment(s).
What are MS patients' experiences with Cladribine intravenous treatment for MS?
(This is not the same treatment as the Cladribine pill that never got FDA approval. Most Cladribine IV treatments are intended to permanently remove inflammation caused by MS. Drugs like Prednisone are temporary anti-inflammatory agents).
IF you have any questions about this research medication, please speak with YOUR MS Neurologist.
Commonly used brand name(s)
Uses For cladribine
- Cancer of the blood and lymph system
- Waldenström's macroglobulinemia (a certain type of cancer of the blood)
Before Using cladribine
PLUS other information found here
Disclaimer - MS Views and News/Stu's Views and MS News are solely providers of information. PLEASE ONLY consult with your MS Neurologist or other healthcare provider(s) for any questions you have regarding this or any other treatment for Multiple Sclerosis or other health related items.
Please be sensible to speak with healthcare providers pertaining to the topic or question.
Wednesday, January 14, 2015
Stem Cell News Alert -- City man who ran stem-cell trial for MS patients fabricated THE credentials, overstated results
This week Congressman Van Hollen (D-MD) and Congressman Burgess, MD (R-TX) introduced bipartisan legislation to improve the understanding of and accelerate research for neurological diseases, including multiple sclerosis.
This legislation, the Advancing Research for Neurological Diseases Act (H.R. 292), will guide the Centers for Disease Control and Prevention in tracking the incidence and prevalence of neurological diseases. According to its cosponsors, this new surveillance system could one day lead to a cure for diseases like multiple sclerosis, as information collected will provide a foundation for evaluating and understanding aspects of these diseases on which we currently do not have a good grasp – such as the geography of diagnoses, variances in gender, disease burden and changes in healthcare practices among patients.
“We are encouraged by the potential this bill has to accelerate research for multiple sclerosis,” Cynthia Zagieboylo, President and CEO of the National Multiple Sclerosis Society, said. “Without basic data concerning the size and makeup of the MS population, our researchers are working at a distinct disadvantage because they have an incomplete picture of the disease. The additional information that this new data system would supply could point to new environmental triggers for the disease, which could lead to new treatment targets and a better understanding of the disease.”
Please ask your U.S. Representative to show his/her support by cosponsoring the Advancing Research for Neurological Disease Act TODAY!
650 Illinois residents are approved to buy medical cannabis in the state. With no available marijuana and little government support, they may be waiting indefinitely.
Tuesday, January 13, 2015
a CME program: Assessing Patient Adherence in MS: Clinical Decisions in the Age of Multiple Therapeutic Options
Monday, January 12, 2015
A Seattle man is among two dozen MS patients in a promising clinical trial that found high-dose immune-suppressing drugs and stem-cell transplants may stop the progress of the disease in those who've failed usual care.
Seven years ago, Mike Kearny of Seattle was so sick and weak from multiple sclerosis, he had to use the handrail to pull himself up the stairs of his Wallingford neighborhood home.
“I was not doing well,” recalled Kearny, now 47, who was first diagnosed in 2006.